Last reviewed 2026-04-22 · How we verify

BMS-986393

BMS-986393 is a CAR-T cell therapy that redirects patient T cells to recognize and kill cancer cells expressing the CD19 antigen.

BMS-986393 is a CAR-T cell therapy that redirects patient T cells to recognize and kill cancer cells expressing the CD19 antigen. Used for Relapsed or refractory B-cell non-Hodgkin lymphoma, Relapsed or refractory chronic lymphocytic leukemia.

At a glance

Mechanism of action

BMS-986393 involves engineering a patient's own T cells to express a chimeric antigen receptor (CAR) that targets CD19, a surface protein commonly found on B-cell malignancies. Once infused back into the patient, these CAR-T cells proliferate and attack CD19-positive cancer cells. This approach leverages the patient's immune system for durable anti-tumor activity.

Approved indications

• Relapsed or refractory B-cell non-Hodgkin lymphoma
• Relapsed or refractory chronic lymphocytic leukemia

Common side effects

• Cytokine release syndrome
• Immune effector cell-associated neurotoxicity syndrome (ICANS)
• Cytopenias
• Infections

Key clinical trials

• A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2) (PHASE3)
• A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma (PHASE1)
• Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.